{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,14]],"date-time":"2026-04-14T23:44:12Z","timestamp":1776210252101,"version":"3.50.1"},"reference-count":30,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"9","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2013,9]]},"DOI":"10.1097\/fpc.0b013e3283647c33","type":"journal-article","created":{"date-parts":[[2013,7,11]],"date-time":"2013-07-11T12:26:10Z","timestamp":1373545570000},"page":"487-493","source":"Crossref","is-referenced-by-count":33,"title":["The effect of the Taq1A variant in the dopamine D2 receptor gene and common CYP2D6 alleles on prolactin levels in risperidone-treated boys"],"prefix":"10.1097","volume":"23","author":[{"given":"Yvette","family":"Roke","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Peter N.","family":"van Harten","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Barbara","family":"Franke","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tessel E.","family":"Galesloot","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Annemieke M.","family":"Boot","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jan K.","family":"Buitelaar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","reference":[{"key":"R3-5-20210213","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1089\/cap.2008.093","article-title":"Aripiprazole in pervasive developmental disorder not otherwise specified and Aspergers disorder: a 14-week, prospective, open-label study.","volume":"19","author":"Stigler","year":"2009","journal-title":"J Child Adolesc Psychopharmacol"},{"key":"R4-5-20210213","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1007\/s11940-010-0091-8","article-title":"Pharmacologic treatment of behavioral symptoms associated with autism and other pervasive developmental disorders.","volume":"12","author":"Wink","year":"2010","journal-title":"Curr Treat Options Neurol"},{"key":"R5-5-20210213","doi-asserted-by":"crossref","first-page":"1050","DOI":"10.4065\/80.8.1050","article-title":"Medication-induced hyperprolactinemia.","volume":"80","author":"Molitch","year":"2005","journal-title":"Mayo Clin Proc"},{"key":"R6-5-20210213","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1080\/09540260801889179","article-title":"Monitoring and management of antipsychotic-related metabolic and endocrine adverse events in pediatric patients.","volume":"20","author":"Correll","year":"2008","journal-title":"Int Rev Psychiatry"},{"key":"R7-5-20210213","first-page":"26","article-title":"Assessing and maximizing the safety and tolerability of antipsychotics used in the treatment of children and adolescents.","volume":"69","author":"Correll","year":"2008","journal-title":"J Clin Psychiatry"},{"key":"R9-5-20210213","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/S0306-4530(02)00112-9","article-title":"Elevated prolactin levels in patients with schizophrenia: mechanisms and related adverse effects.","volume":"28","author":"Halbreich","year":"2003","journal-title":"Psychoneuroendocrinology"},{"key":"R10-5-20210213","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1192\/bjp.bp.106.023671","article-title":"Risk of hip fracture in patients with a history of schizophrenia.","volume":"190","author":"Howard","year":"2007","journal-title":"Br J Psychiatry"},{"key":"R11-5-20210213","doi-asserted-by":"crossref","first-page":"338","DOI":"10.4088\/JCP.08m04595gre","article-title":"A cross-sectional evaluation of the effect of risperidone and selective serotonine reuptake inhibitors on bone mineral density in boys.","volume":"1","author":"Calarge","year":"2010","journal-title":"J Clin Psychiatry"},{"key":"R12-5-20210213","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1159\/000337910","article-title":"Antipsychotic-induced hyperprolactinemia and testosterone levels in boys.","volume":"77","author":"Roke","year":"2012","journal-title":"Horm Res Paediatr"},{"key":"R13-5-20210213","doi-asserted-by":"crossref","first-page":"1523","DOI":"10.1152\/physrev.2000.80.4.1523","article-title":"Prolactin: structure, function, and regulation of secretion.","volume":"80","author":"Freeman","year":"2000","journal-title":"Physiol Rev"},{"key":"R14-5-20210213","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1097\/00008571-199712000-00006","article-title":"D2 dopamine receptor gene (DRD2) Taq1 A polymorphism: reduced dopamine D2 receptor binding in the human striatum associated with the A1 allele.","volume":"7","author":"Thompson","year":"1997","journal-title":"Pharmacogenetics"},{"key":"R18-5-20210213","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1097\/JCP.0b013e31822cfff2","article-title":"DRD2 Taq1A polymorphism modulates prolactin secretion induced by atypical antipsychotics in healthy volunteers.","volume":"31","author":"Lopez-Rodriguez","year":"2011","journal-title":"J Clin Psychopharmacol"},{"key":"R19-5-20210213","doi-asserted-by":"crossref","first-page":"1491","DOI":"10.1016\/j.pnpbp.2008.05.006","article-title":"Association between dopamine-related polymorphisms and plasma concentrations of prolactin during risperidone treatment in schizophrenic patients.","volume":"32","author":"Yasui-Furukori","year":"2008","journal-title":"Prog Neuropsychopharmacol Biol Psychiatry"},{"key":"R20-5-20210213","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1097\/FPC.0b013e328329a60f","article-title":"Variants of the dopamine D2 receptor gene and risperidone-induced hyperprolactinemia in children and adolescents.","volume":"19","author":"Calarge","year":"2009","journal-title":"Pharmacogenet Genomics"},{"key":"R21-5-20210213","first-page":"284","article-title":"Cytochrome P450 2D6 variants in a Caucasian population: allele frequencies and phenotypic consequences.","volume":"60","author":"Sachse","year":"1997","journal-title":"Am J Hum Genet"},{"key":"R22-5-20210213","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1097\/JCP.0b013e3181c17df0","article-title":"Impact of CYP2D6 genotype on steady-state serum concentrations of risperidone and 9-hydroxyrisperidone in patients using long-acting injectable risperidone.","volume":"29","author":"Hendset","year":"2009","journal-title":"J Clin Psychopharmacol"},{"key":"R23-5-20210213","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1089\/cap.2010.0038","article-title":"Predictors of risperidone and 9-hydroxyrisperidone serum concentration in children and adolescents.","volume":"21","author":"Calarge","year":"2011","journal-title":"J Child Adolesc Psychopharmacol"},{"key":"R24-5-20210213","doi-asserted-by":"crossref","first-page":"469","DOI":"10.4088\/JCP.v60n0709","article-title":"A pilot study on risperidone metabolism: the role of cytochromes P450 2D6 and 3A.","volume":"60","author":"Bork","year":"1999","journal-title":"J Clin Psychiatry"},{"key":"R26-5-20210213","doi-asserted-by":"crossref","first-page":"15","DOI":"10.4088\/JCP.v66n0103","article-title":"The CYP2D6 poor metabolizer phenotype may be associated with risperidone adverse drug reactions and discontinuation.","volume":"66","author":"De Leon","year":"2005","journal-title":"J Clin Psychiatry"},{"key":"R28-5-20210213","doi-asserted-by":"crossref","first-page":"23","DOI":"10.2165\/00024677-200302010-00003","article-title":"Hyperprolactinemia: pathophysiology and management.","volume":"2","author":"Verhelst","year":"2003","journal-title":"Treat Endocrinol"},{"key":"R31-5-20210213","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1136\/adc.82.2.107","article-title":"Body index measurements in 1996-7 compared with 1980.","volume":"82","author":"Fredriks","year":"2000","journal-title":"Arch Dis Child"},{"key":"R32-5-20210213","first-page":"1151","article-title":"Reference ranges for serum concentrations of Lutotropin (LH), Follitropin (FSH), Estradiol (E2), Prolactin, Progesterone, Sex Hormone Binding Globuline (SHBG), Dehydroepiandrosterone sulfate (DHEAS), Cortisol and Ferritin in neonates, children and young adults.","volume":"40","author":"Emlinger","year":"2002","journal-title":"Clin Chem Lab Med"},{"key":"R34-5-20210213","doi-asserted-by":"crossref","first-page":"504","DOI":"10.1097\/JCP.0b013e3181ee84c7","article-title":"Effects of CYP2D6 genotype on the pharmacokinetics, pharmacodynamics, and safety of risperidone in healthy volunteers.","volume":"30","author":"Novalbos","year":"2010","journal-title":"J Clin Psychopharmacol"},{"key":"R36-5-20210213","doi-asserted-by":"crossref","first-page":"29","DOI":"10.2165\/00003088-198900171-00005","article-title":"Clinical pharmacokinetics in infants and children: a reappraisal.","volume":"17","author":"Kearns","year":"1989","journal-title":"Clin Pharmacokinet"},{"key":"R37-5-20210213","doi-asserted-by":"crossref","first-page":"1010","DOI":"10.1176\/appi.ajp.162.5.1010","article-title":"Predominant role of the 9-hydroxy metabolite of risperidone in elevating blood prolactin levels.","volume":"162","author":"Knegtering","year":"2005","journal-title":"Am J Psychiatry"},{"key":"R38-5-20210213","doi-asserted-by":"crossref","first-page":"2247","DOI":"10.1016\/0024-3205(87)90060-9","article-title":"Effects of acute and chronic methylphenidate administration on beta-endorphin, growth hormone, prolactin and cortisol in children with attention deficit disorder and hyperactivity.","volume":"40","author":"Weizman","year":"1987","journal-title":"Life Sci"},{"key":"R39-5-20210213","doi-asserted-by":"crossref","first-page":"648","DOI":"10.1001\/archpsyc.1991.01810310066012","article-title":"Allelic association of the D2 dopamine receptor gene with receptor-binding characteristics in alcoholism.","volume":"48","author":"Noble","year":"1991","journal-title":"Arch Gen Psychiatry"},{"key":"R42-5-20210213","doi-asserted-by":"crossref","first-page":"563","DOI":"10.2165\/11533140-000000000-00000","article-title":"Antidepressant-induced hyperprolactinaemia.","volume":"24","author":"Coker","year":"2010","journal-title":"CNS Drugs"},{"key":"R43-5-20210213","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1002\/cbf.1258","article-title":"Characterization of variant alleles of cytochrome CYP2D6 in a Spanish population.","volume":"24","author":"Menoyo","year":"2006","journal-title":"Cell Biochem Funct"},{"key":"R45-5-20210213","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1089\/cap.2006.16.317","article-title":"The effect of long-term antipsychotic treatment on prolactin.","volume":"16","author":"Staller","year":"2006","journal-title":"J Child Adolesc Psychopharmacol"}],"container-title":["Pharmacogenetics and Genomics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/FPC.0b013e3283647c33","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,5,14]],"date-time":"2021-05-14T00:27:47Z","timestamp":1620952067000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/01213011-201309000-00005"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,9]]},"references-count":30,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2013]]}},"URL":"https:\/\/doi.org\/10.1097\/fpc.0b013e3283647c33","relation":{},"ISSN":["1744-6872"],"issn-type":[{"value":"1744-6872","type":"print"}],"subject":[],"published":{"date-parts":[[2013,9]]}}}